UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000051854 |
|---|---|
| Receipt number | R000058793 |
| Scientific Title | Verification of effects by test-food intakes on gut microenvironment and immunity |
| Date of disclosure of the study information | 2024/08/07 |
| Last modified on | 2024/04/23 18:29:00 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Verification of effects by test-food intakes on gut microenvironment and immunity
Acronym
Verification of effects by test-food intakes on gut microenvironment and immunity
Scientific Title
Verification of effects by test-food intakes on gut microenvironment and immunity
Scientific Title:Acronym
Verification of effects by test-food intakes on gut microenvironment and immunity
Region
| Japan |
Condition
Condition
Male/female adults
Classification by specialty
| Adult |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To confirm some kind of effect by the test-food intakes for four weeks on gut microenvironment and immunity
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Intestinal flora (next generation-targeted amplicon sequencing analysis)
Key secondary outcomes
1. Defecation status (the number of days, frequency, quantity, property, color, fecal odor, feeling of incomplete evacuation, abdominal pain)
2. Physicochemical tests in feces (short chain fatty acids, ammonia, spoiled products, pH, water, and IgA)
3. Immunological tests in blood (NK-cell activity)
4. Constipation assessment scale-mid term
5. Clinical examination values
Base
Study type
Interventional
Study design
Basic design
Cross-over
Randomization
Randomized
Randomization unit
Individual
Blinding
Double blind -all involved are blinded
Control
Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
2
Purpose of intervention
Prevention
Type of intervention
| Food |
Interventions/Control_1
Consumption of the test food (10 capsules a day) with water/lukewarm water to the subjects for four weeks.
Interventions/Control_2
Consumption of the placebo food (10 capsules a day) with water/lukewarm water to the subjects for four weeks.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 65 | years-old | > |
Gender
Male and Female
Key inclusion criteria
1 Male/female subjects ranging in age from 20 to 64, at informed consent.
2 Subjects ranging in defection frequency from not less than three times to no more than five times a week.
3 Subjects who can give informed consent to participate in this research, after being provided with an explanation of the protocol detail.
Key exclusion criteria
Subjects
1 who take steadily (not less than 3 times a week) in the health-specific/
functional/supplementary/health foods, yogurts or lactic acid bacteria beverages, which might affect the test results (intestinal regulation and immune maintenance).
2 who have taken affecting medicines (e.g., allergic/antibiotic/gut/laxative regulation) except eye/nose drops, within the last month before the hospital visiting (0 W at the first stage).
3 who will vaccinate within after the time point of pre-test, and before the hospital visiting (4 W at the second stage) during this research.
4 who had undergone appendectomy.
5 who have received the affecting surgery (e.g. colonoscopy, removal of gallstones and/or gall bladder, or gastric bypass surgery) within half a year before obtaining the consent.
6 who take excessive alcohol.
7 with extremely irregular dietary habits.
8 who will change their life style, dietary habit, and living environment (e.g., move, transfer) during this research.
9 who are now under another clinical test with some kind of medicine and/or health food, or took part in that within four weeks before this research, or will participate in that after giving informed consent to take part in this research.
10 whose roomer is planning to partake in this research.
11 who have previous/current medical history of severe cardiac, hepatic, renal or digestive diseases.
12 pregnant, possibly pregnant, or lactating women.
13 having drug and/or food allergy.
14 who donated their blood components or blood (0.2 L) within the last month,
15 who donated his blood (0.4 L) within the last 3 months,
16 who donated her blood (0.4 L) within the last 4 months,
17 being collected in total of his blood (1.2 L) within the last 12 months and in this research,
18 being collected in total of her blood (0.8 L) within the last 12 months and in this research
19 who have been determined as ineligible for participation, judging from the principal/sub investigator's opinions.
Target sample size
34
Research contact person
Name of lead principal investigator
| 1st name | Fumiko |
| Middle name | |
| Last name | Nakamura |
Organization
CPCC Company Limited
Division name
Clinical Support Department
Zip code
103-0021
Address
4F Daiwa Building, 3-3-10 Nihonbashi-Hongoku-Cho, Chuo-ku, Tokyo 103-0021, Japan
TEL
03-6225-9001
cpcc-contact@cpcc.co.jp
Public contact
Name of contact person
| 1st name | Makoto |
| Middle name | |
| Last name | Ichinohe |
Organization
CPCC Company Limited
Division name
Clinical Planning Department
Zip code
103-0021
Address
4F Daiwa Building, 3-3-10 Nihonbashi-Hongoku-Cho, Chuo-ku, Tokyo 103-0021, Japan
TEL
03-6225-9001
Homepage URL
cpcc-contact@cpcc.co.jp
Sponsor or person
Institute
CPCC Company Limited
Institute
Department
Personal name
Funding Source
Organization
Nisshin Seifun Group Inc.
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Institutional Review Board of Chiyoda Paramedical Care Clinic
Address
2F Daiwa Building, 3-3-10 Nihonbashi-Hongoku-Cho, Chuo-ku, Tokyo 103-0021, Japan
Tel
03-6225-9005
IRB@cpcc.co.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2024 | Year | 08 | Month | 07 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2023 | Year | 05 | Month | 25 | Day |
Date of IRB
| 2022 | Year | 07 | Month | 15 | Day |
Anticipated trial start date
| 2023 | Year | 08 | Month | 07 | Day |
Last follow-up date
| 2023 | Year | 11 | Month | 28 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2023 | Year | 08 | Month | 07 | Day |
Last modified on
| 2024 | Year | 04 | Month | 23 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000058793
